Fosinopril
Sponsors
Novartis Pharma AG, Medical University Of Vienna, Policlinico San Donato S.p.A., National Heart, Lung, and Blood Institute (NHLBI), Radboud University Medical Center
Conditions
Cardiovascular DiseasesChronic Kidney DiseaseChronic Obstructive Pulmonary DiseaseDiabetes MellitusDiabetes mellitus Type 2Diabetic NephropathyEssential HypertensionHeart Diseases
Phase 2
ACE Inhibition and Novel Cardiovascular Risk Factors
CompletedNCT00051389
Start: 2002-02-28End: 2007-01-31Updated: 2016-02-18
Eplerenone, ACE Inhibition and Albuminuria
CompletedNCT00315016
Start: 2007-01-31End: 2011-07-31Updated: 2012-05-28
A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure
CompletedCTIS2023-504678-39-00
Start: 2024-03-13End: 2024-11-08Target: 424Updated: 2024-11-08
Phase 3
Phase 4
Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01014338
Start: 2009-10-31End: 2012-09-30Updated: 2015-03-25
Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension
NCT02646397
Start: 2016-02-29End: 2017-12-31Target: 508Updated: 2016-01-05
NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
Not yet recruitingCTIS2024-519051-28-01
Target: 448Updated: 2025-02-17
Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)
Not yet recruitingCTIS2025-520660-18-00
Target: 368Updated: 2025-11-17